Antipsychotic drug doses and neuroleptic/dopamine receptors

Antipsychotic Drugs: Direct Correlation Between Clinical Potency and Presynaptic Action on Dopamine Neurons

Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · see citing works

Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

Seeman, P. M., Chau-Wong, M., Tedesco, J., & Wong, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4376 · Cited by 702 · see citing works

Dopamine Receptors in the Brain

Iversen, L. L. (1975) · Science · doi:10.1126/science.2976 · Cited by 530 · see citing works

Dopamine receptor binding: Differentiation of agonist and antagonist states with 3H-dopamine and 3H-haloperidol

Creese, I., Burt, D. R., & Snyder, S. H. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90454-3 · Cited by 389 · see citing works

Dopamine receptor binding in the corpus striatum of mammalian brain.

Burt, D. R., Enna, S. J., Creese, I., & Snyder, S. H. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4655 · Cited by 220 · see citing works

Physiologic and clinical effects of chlorpromazine and their relationship to plasma level

Sakalis, G., Curry, S. H., Mould, G. P., et al. (1972) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1972136931 · Cited by 141 · see citing works

A gas chromatographic method for determining haloperidol

Forsman, A., M�rtensson, E., Nyberg, G., et al. (1974) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00501606 · Cited by 82 · see citing works

THE NERVE IMPULSE-BLOCKING ACTIONS OF TRANQUILIZERS AND THE BINDING OF NEUROLEPTICS TO SYNAPTOSOME MEMBRANES

Seeman, P. M., Staiman, A., & Chau-Wong, M. (1974) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29901-3 · Cited by 59 · see citing works

Dopamine receptor blockade and the neuroleptics, a crystallographic study

Horn, A. S., Post, M. L., & Kennard, O. (1975) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1975.tb09506.x · Cited by 44 · see citing works

Plasma-level studies of chlorpromazine following the administration of chlorpromazine hydrochloride and chlorpromazine embonate in chronic schizophrenics.

Sf, C., Jm, A., Hillel, J., et al. (1973) · PubMed · Cited by 7 · see citing works

An early clinical trial of lenperone (AHR 2277), a butyrophenone, in chronic schizophrenia.

Gm, S., & Varga, V. (1974) · PubMed · Cited by 3 · see citing works

The physiology, signaling, and pharmacology of dopamine receptors

Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · see citing works

Psychosis as a state of aberrant salience: a framework linking biology, phenomenology and pharmacology in schizophrenia

Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813 · see citing works

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693 · see citing works

Schizophrenia

Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870 · see citing works

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia

Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831 · see citing works

Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex

Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · see citing works

Relationship Between Dopamine D ₂ Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode Schizophrenia

Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090 · see citing works

Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia

Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075 · see citing works

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works

Glutamate and dopamine in schizophrenia: An update for the 21 ^st century

Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702 · see citing works

Half a century of antipsychotics and still a central role for dopamine D2 receptors

Kapur, S., & Mamo, D. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.004 · Cited by 638 · see citing works

Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia

Meyer, U., Feldon, J., Schedlowski, M., & Yee, B. K. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.10.012 · Cited by 494 · see citing works

Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected

Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408 · see citing works

Imaging endogenous dopamine competition with [¹¹C]raclopride in the human brain

Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Schlyer, D., Hitzemann, R., Lieberman, J., Angrist, B., Pappas, N., MacGregor, R., et al. (1994) · Synapse · doi:10.1002/syn.890160402 · Cited by 379 · see citing works

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359 · see citing works

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

Kapur, S., & Remington, G. (2001) · Annual Review of Medicine · doi:10.1146/annurev.med.52.1.503 · Cited by 324 · see citing works

Selective D2 receptor actions on the functional circuitry of working memory

Wang, M., Vijayraghavan, S., & Goldman-Rakic, P. S. (2004) · Science · doi:10.1126/science.1091162 · Cited by 319 · see citing works

Schizophrenia: More dopamine, more D ₂ receptors

Seeman, P., & Kapur, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7673 · Cited by 279 · see citing works

Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy

Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works

The neural basis of hallucinations and delusions

Frith, C. (2004) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.012 · Cited by 248 · see citing works

All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228 · see citing works

Neuronal defects in a human cellular model of 22q11.2 deletion syndrome

Khan, T. A., Revah, O., Gordon, A., Yoon, S.-J., Krawisz, A. K., Goold, C., Sun, Y., Kim, C. H., Tian, Y., Li, M.-Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1043-9 · Cited by 186 · see citing works

Regulation of NMDA Receptors by Dopamine D₄Signaling in Prefrontal Cortex

Wang, X., Zhong, P., Gu, Z., & Yan, Z. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09852.2003 · Cited by 159 · see citing works

The natural history and pathophysiology of treatment resistant schizophrenia

Sheitman, B. B., & Lieberman, J. A. (1998) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00052-6 · Cited by 140 · see citing works

Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders

Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132 · see citing works

DISC1: Structure, Function, and Therapeutic Potential for Major Mental Illness

Soares, D. C., Carlyle, B. C., Bradshaw, N. J., & Porteous, D. J. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200062k · Cited by 129 · see citing works

Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson’s disease and schizophrenia

Ichinose, H., Ohye, T., Fujita, K., Pantucek, F., Lange, K., Riederer, P., & Nagatsu, T. (1994) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02250926 · Cited by 107 · see citing works

Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application

Leucht, S., Priller, J., & Davis, J. M. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240738 · Cited by 117 · see citing works

The role of cortical inhibition in the pathophysiology and treatment of schizophrenia

Daskalakis, Z. J., Fitzgerald, P. B., & Christensen, B. K. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.006 · Cited by 111 · see citing works

Understanding the Mechanism of Action of Atypical Antipsychotic Drugs: A Review of Compounds in Use and Development

Lieberman, J. A. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292544 · Cited by 108 · see citing works

The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex

Mirjana, C., Baviera, M., Invernizzi, R. W., & Balducci, C. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300479 · Cited by 102 · see citing works

Reality of auditory verbal hallucinations

Raij, T. T., Valkonen-Korhonen, M., Holi, M., Therman, S., Lehtonen, J., & Hari, R. (2009) · Brain · doi:10.1093/brain/awp186 · Cited by 95 · see citing works

Drugs affecting body weight, body fat distribution, and metabolic function—mechanisms and possible therapeutic or preventive measures: an update.

Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53 · see citing works

Antipsychotics, dopamine D₂ receptor occupancy and clinical improvement in schizophrenia: a meta-analysis

Yilmaz, Z., Zai, C. C., Hwang, R., Mann, S., Arenovich, T., Remington, G., & Daskalakis, Z. J. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.027 · Cited by 52 · see citing works

D₂ but not D₃ receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period

Joyce, J. N. (2001) · Synapse · doi:10.1002/syn.1035 · Cited by 47 · see citing works

Antidepressants, β-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions

Golan, M., Schreiber, G., & Avissar, S. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168038 · Cited by 22 · see citing works

Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure

Wang, X., Gu, Z., Zhong, P., Chen, G., Feng, J., & Yan, Z. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.08.018 · Cited by 16 · see citing works

Evaluation of the reinforcing effect of quetiapine, alone and in combination with cocaine, in Rhesus monkeys

Brutcher, R. E., Nader, S. H., & Nader, M. A. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228577 · Cited by 11 · see citing works

The affinity of D2-like dopamine receptor antagonists determines the time to maximal effect on cocaine self-administration

Norman, A. B., Tabet, M. R., Norman, M. K., Fey, B. K., Tsibulsky, V. L., & Millard, R. W. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183244 · Cited by 10 · see citing works

The effect of ethanol and haloperidol on dopamine receptor (D2) density

Fuchs, V., Coper, H., & Rommelspacher, H. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90274-7 · Cited by 23 · see citing works

Double-blind- evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients.

Malfroid, M., Hens, L., Roosen, P., et al. (1978) · PubMed · Cited by 12 · see citing works

Disruption of dopamine D1/D2 receptor complex is involved in the function of haloperidol in cardiac H9c2 cells

Lencesova, L., Szadvári, I., Babula, P., Kubíčková, J., Chovancova, B., Lopušná, K., Režuchová, I., Nováková, Z., Križanová, O., & Nováková, M. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.10.026 · Cited by 6 · see citing works

Behavioral pharmacological studies of OPC-14597, a novel antipsychotic drug : Comparison with OPC-4392, clozapine and haloperidol.

Kikuchi, T., Uwahodo, Y., Tottori, K., et al. (1996) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)36980-x

REMOXIPRIDE - A POTENTIAL ANTIPSYCHOTIC DRUG WITH SELECTIVE DOPAMINE D2 RECEPTOR PROPERTIES

Widerlöv, E. (1984) · Clinical Neuropharmacology · doi:10.1097/00002826-198406001-00273 · Cited by 7 · see citing works